NO913117L - Fremgangsmaate for behandling av benoedeleggende sykdommer. - Google Patents

Fremgangsmaate for behandling av benoedeleggende sykdommer.

Info

Publication number
NO913117L
NO913117L NO91913117A NO913117A NO913117L NO 913117 L NO913117 L NO 913117L NO 91913117 A NO91913117 A NO 91913117A NO 913117 A NO913117 A NO 913117A NO 913117 L NO913117 L NO 913117L
Authority
NO
Norway
Prior art keywords
diseases
procedure
treatment
necessary
necessary diseases
Prior art date
Application number
NO91913117A
Other languages
English (en)
Other versions
NO913117D0 (no
Inventor
Keith T Demarest
David J Baylink
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of NO913117D0 publication Critical patent/NO913117D0/no
Publication of NO913117L publication Critical patent/NO913117L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO91913117A 1990-08-10 1991-08-09 Fremgangsmaate for behandling av benoedeleggende sykdommer. NO913117L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56576390A 1990-08-10 1990-08-10

Publications (2)

Publication Number Publication Date
NO913117D0 NO913117D0 (no) 1991-08-09
NO913117L true NO913117L (no) 1992-02-11

Family

ID=24259992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91913117A NO913117L (no) 1990-08-10 1991-08-09 Fremgangsmaate for behandling av benoedeleggende sykdommer.

Country Status (13)

Country Link
EP (1) EP0474374A1 (no)
JP (1) JPH04230632A (no)
KR (1) KR930003924A (no)
AU (1) AU8166191A (no)
CA (1) CA2048810A1 (no)
FI (1) FI913791A (no)
HU (1) HUT59605A (no)
IE (1) IE912832A1 (no)
IL (1) IL99123A0 (no)
NO (1) NO913117L (no)
PT (1) PT98626A (no)
ZA (1) ZA916317B (no)
ZW (1) ZW11391A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710144A (en) * 1993-02-08 1998-01-20 Akzo Nobel N.V. C-11 substituted steroids for treating menopausal complaints
ZA94715B (en) * 1993-02-08 1994-10-24 Akzo Nv Steroids for treating menopausal complaints
US6037339A (en) * 1993-02-08 2000-03-14 Akzo Nobel N.V. C-11 substituted steroids for treating menopausal complaints
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
DE19815060A1 (de) * 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
AU2223600A (en) * 1999-01-06 2000-07-24 Cedars-Sinai Medical Center Hormone replacement for breast cancer patients
CA2487655A1 (en) * 2002-05-24 2003-12-04 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting hiv replication
KR101586336B1 (ko) * 2014-08-06 2016-01-18 한국생명공학연구원 에스트로피페이트(Estropipate) 또는 이의 약학적으로 허용 가능한 염을 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
CN110809473A (zh) * 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226316A (en) * 1987-09-24 1991-10-25 Jencap Research Ltd Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance
HUT52382A (en) * 1988-03-14 1990-07-28 Sandoz Ag Process for producing pharmaceutical compositions comprising as active ingredient unsubstituted progestin in 19-position and estrogen in the given case

Also Published As

Publication number Publication date
CA2048810A1 (en) 1992-02-11
IE912832A1 (en) 1992-02-12
IL99123A0 (en) 1992-07-15
AU8166191A (en) 1992-02-13
ZA916317B (en) 1993-04-28
ZW11391A1 (en) 1993-04-07
PT98626A (pt) 1992-06-30
HU912646D0 (en) 1992-01-28
EP0474374A1 (en) 1992-03-11
NO913117D0 (no) 1991-08-09
FI913791A (fi) 1992-02-11
FI913791A0 (fi) 1991-08-09
JPH04230632A (ja) 1992-08-19
HUT59605A (en) 1992-06-29
KR930003924A (ko) 1993-03-22

Similar Documents

Publication Publication Date Title
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
NO934304L (no) Fremgangsmaate for behandling av fluoralumosilikatglass
NO894296D0 (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
NO911934D0 (no) Fremgangsmaate for fremstilling av bicykliske 1-aza-cykloalkaner.
NO912051D0 (no) Fremgangsmaate for fremstilling av azolderivater.
IT9047580A0 (it) Procedimento di trattamento di polveri inorganiche.
NO910395D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 4-isoxazolcarboxamidderivater.
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
NO912346D0 (no) Fremgangsmaate for fremstilling av aminobenzodiazepiner.
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
NO911122D0 (no) Fremgangsmaate for fremstilling av antihyperkolesterolemiske midler.
NO911606L (no) Fremgangsmaate for fremstilling av glycidylazidpolymer.
NO912242D0 (no) Sorpsjon av trialkylarsiner.
NO912797L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme karbostirilderivater.
NO912158D0 (no) Behandling av undergrunnsformasjon.
NO913117D0 (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
NO892505D0 (no) Behandling av vandige dispersjoner.
NO880292L (no) Fremgangsmaate for behandling av humle.
NO913692D0 (no) Fremgangsmaate for fremstilling av karbapenemforbindelser.
NO920983D0 (no) Fremgangsmaate for behandling av nevrodegenerative tilstander
NO910018D0 (no) Fremgangsmaate for fremstilling av flerumettede fettsyrer.
NO900381D0 (no) Fremgangsmaate for fremstilling av nafthalenderivater.
NO884635D0 (no) Fremgangsmaate for behandling av most.
NO905643L (no) Fremgangsmaate for behandling av manganslam.
FI913414A0 (fi) Foerfarande foer framstaellning av 2-hydroxi-3-halogen-5-nitropyridiner.